{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:47:35Z","timestamp":1785833255176,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ASCO Conquer Cancer Foundation Young Investigator Award"},{"DOI":"10.13039\/100013684","name":"Christie Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>PRELUDE aimed to assess use and effectiveness\/safety of lanreotide autogel\/depot (LAN) combined with <jats:sup>177<\/jats:sup>Lu-DOTATOC or <jats:sup>177<\/jats:sup>Lu-DOTATATE (LAN\u2013peptide receptor radionuclide therapy [PRRT]) in patients with progressive neuroendocrine tumours (NETs).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>International, non-interventional, retrospective, non-comparative analysis of medical records from patients with progressive metastatic or locally advanced grade 1 or 2 gastroenteropancreatic (GEP)- or lung-NETs. The primary endpoint was progression-free survival (PFS) at end of last LAN\u2013PRRT cycle. Secondary endpoints included PFS at last available follow-up, best overall response, objective response rate (ORR), presence and severity of diarrhoea and flushing, and safety. Post-hoc analyses were conducted to determine pre-treatment tumour growth rate (TGR) cutoffs that best predicted the ORR during treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Forty patients were enrolled (GEP-NETs, <jats:italic>n<\/jats:italic>\u2009=\u200939; lung-NETs, <jats:italic>n<\/jats:italic>\u2009=\u20091). PFS rates were 91.7% at end of last LAN\u2013PRRT cycle and 95.0% at last available follow-up. In the full analysis set, best overall response among patients with GEP-NETs (<jats:italic>n<\/jats:italic>\u2009=\u200923) was stable disease (<jats:italic>n<\/jats:italic>\u2009=\u200914, 60.9%), partial response (<jats:italic>n<\/jats:italic>\u2009=\u20098, 34.8%) and progressive disease (<jats:italic>n<\/jats:italic>\u2009=\u20091, 4.3%). The ORR was 27.3% at end of last LAN\u2013PRRT cycle and 36.8% at last available follow-up. Optimal baseline TGR cutoffs for predicting ORR at these time points were 1.18% and 0.33%, respectively. At baseline, 81.0% of patients had diarrhoea or flushing; both remained stable or improved in most cases. No increased adverse drug reactions were reported.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Despite the major recruitment shortfall for the PRELUDE study, effectiveness data were encouraging in this selected population, highlighting the potential usefulness and feasibility of LAN combined with and after PRRT in patients with GEP-NETs. The study also identified challenges associated with evaluating clinical practice in a rare-disease setting and highlighted the need for standardisation of PRRT procedures.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Trial number: NCT02788578; URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02788578\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02788578<\/jats:ext-link><\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00259-020-04712-2","type":"journal-article","created":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T10:02:28Z","timestamp":1581760948000},"page":"2358-2371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2010-4117","authenticated-orcid":false,"given":"Vikas","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Srirajaskanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Grana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Scheidhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Mai","family":"Truong Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Dromain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"issue":"2","key":"4712_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11154-018-9465-0","volume":"19","author":"S Pedraza-Arevalo","year":"2018","unstructured":"Pedraza-Arevalo S, Gahete MD, Alors-Perez E, Luque RM, Castano JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord. 2018;19(2):179\u201392. https:\/\/doi.org\/10.1007\/s11154-018-9465-0.","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"4712_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1677\/erc-07-0288","volume":"15","author":"S Grozinsky-Glasberg","year":"2008","unstructured":"Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer. 2008;15(3):701\u201320. https:\/\/doi.org\/10.1677\/erc-07-0288.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"4712_CR3","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1158\/1078-0432.ccr-12-3458","volume":"19","author":"K Oberg","year":"2013","unstructured":"Oberg K, Casanovas O, Castano JP, Chung D, Delle Fave G, Denefle P, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013;19(11):2842\u20139. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-3458.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"4712_CR4","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","volume":"26","author":"ME Caplin","year":"2015","unstructured":"Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdv041.","journal-title":"Ann Oncol"},{"issue":"2","key":"4712_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385. https:\/\/doi.org\/10.1159\/000443167.","journal-title":"Neuroendocrinology."},{"key":"4712_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. Version 1.2019. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine_blocks.pdf Accessed April 2019."},{"issue":"12","key":"4712_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","volume":"17","author":"C Susini","year":"2006","unstructured":"Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdl105.","journal-title":"Ann Oncol"},{"issue":"2","key":"4712_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"17","key":"4712_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416\u201323. https:\/\/doi.org\/10.1200\/JCO.2010.33.7873.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4712_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","volume":"28","author":"DL Bushnell Jr","year":"2010","unstructured":"Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.22.8585.","journal-title":"J Clin Oncol"},{"key":"4712_CR11","unstructured":"US Food, Drug Administration. Lutathera label. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf. Accessed 28 August 2018."},{"key":"4712_CR12","unstructured":"European Medicines Agency. Lutathera Summary of Product Characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004123\/WC500241595.pdf. Accessed 24 August 2018."},{"key":"4712_CR13","unstructured":"European Medicines Agency. Assessment report - Lutathera. 2017."},{"issue":"16","key":"4712_CR14","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4712_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"issue":"3","key":"4712_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191\u20139. https:\/\/doi.org\/10.1530\/ERC-15-0490.","journal-title":"Endocr Relat Cancer"},{"key":"4712_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/1471-2407-13-427","volume":"13","author":"M Martin-Richard","year":"2013","unstructured":"Martin-Richard M, Massuti B, Pineda E, Alonso V, Marmol M, Castellano D, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013;13:427. https:\/\/doi.org\/10.1186\/1471-2407-13-427.","journal-title":"BMC Cancer"},{"issue":"1","key":"4712_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12885-018-5257-x","volume":"19","author":"C Dromain","year":"2019","unstructured":"Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, et al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer. 2019;19(1):66. https:\/\/doi.org\/10.1186\/s12885-018-5257-x.","journal-title":"BMC Cancer"},{"issue":"1","key":"4712_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","volume":"20","author":"C Ferte","year":"2014","unstructured":"Ferte C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res. 2014;20(1):246\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2098.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4712_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2013.08.010","volume":"65","author":"C Ferte","year":"2014","unstructured":"Ferte C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol. 2014;65(4):713\u201320. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.010.","journal-title":"Eur Urol"},{"issue":"19","key":"4712_CR21","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-18-0947","volume":"24","author":"A Yordanova","year":"2018","unstructured":"Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24(19):4672\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0947.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4712_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/02841868909111193","volume":"28","author":"M Tubiana","year":"1989","unstructured":"Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 1989;28(1):113\u201321.","journal-title":"Acta Oncol"},{"issue":"1","key":"4712_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijrobp.2014.01.038","volume":"89","author":"NN Niu","year":"2014","unstructured":"Niu NN, Niemierko A, Larvie M, Curtin H, Loeffler JS, McKenna MJ, et al. Pretreatment growth rate predicts radiation response in vestibular schwannomas. Int J Radiat Oncol Biol Phys. 2014;89(1):113\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4712_CR24","doi-asserted-by":"publisher","unstructured":"Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, et al. Value of tumor growth rate (TGR) as an early biomarker predictor of patients\u2019 outcome in neuroendocrine tumors (NET)-the GREPONET study. Oncologist. 2019. https:\/\/doi.org\/10.1634\/theoncologist.2018-0672.","DOI":"10.1634\/theoncologist.2018-0672"},{"issue":"3","key":"4712_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295\u2013309. https:\/\/doi.org\/10.1159\/000475526.","journal-title":"Neuroendocrinology."},{"issue":"9","key":"4712_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.4158\/EP151172.OR","volume":"22","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA. * ESG. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068\u201380. https:\/\/doi.org\/10.4158\/EP151172.OR.","journal-title":"Endocr Pract"},{"issue":"24","key":"4712_CR27","doi-asserted-by":"publisher","first-page":"16932","DOI":"10.18632\/oncotarget.24524","volume":"9","author":"RP Baum","year":"2018","unstructured":"Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9(24):16932\u201350. https:\/\/doi.org\/10.18632\/oncotarget.24524.","journal-title":"Oncotarget"},{"issue":"5","key":"4712_CR28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12149-017-1163-6","volume":"31","author":"J Kunikowska","year":"2017","unstructured":"Kunikowska J, Pawlak D, Bak MI, Kos-Kudla B, Mikolajczak R, Krolicki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with (90)Y\/(177)Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017;31(5):347\u201356. https:\/\/doi.org\/10.1007\/s12149-017-1163-6.","journal-title":"Ann Nucl Med"},{"key":"4712_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000402936","volume":"44","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Prasad V, Modlin IM. Peptide receptor radionuclide therapy of neuroendocrine tumors. Front Horm Res. 2015;44:198\u2013215. https:\/\/doi.org\/10.1159\/000402936.","journal-title":"Front Horm Res"},{"issue":"2","key":"4712_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.23736\/S1824-4785.17.03038-2","volume":"62","author":"S Grimaldi","year":"2018","unstructured":"Grimaldi S, Terroir M, Caramella C. Advances in oncological treatment: limitations of RECIST 1.1 criteria. Q J Nucl Med Mol Imaging. 2018;62(2):129\u201339. https:\/\/doi.org\/10.23736\/S1824-4785.17.03038-2.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"9","key":"4712_CR31","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S1470-2045(15)00186-2","volume":"16","author":"K Oberg","year":"2015","unstructured":"Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435\u2013e46. https:\/\/doi.org\/10.1016\/S1470-2045(15)00186-2.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4712_CR32","first-page":"1602","volume":"40","author":"R Lebtahi","year":"1999","unstructured":"Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med. 1999;40(10):1602\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"4712_CR33","first-page":"184","volume":"44","author":"WG Meijer","year":"2003","unstructured":"Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med. 2003;44(2):184\u201391.","journal-title":"J Nucl Med"},{"issue":"4","key":"4712_CR34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1677\/ERC-08-0017","volume":"15","author":"UF Pape","year":"2008","unstructured":"Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15(4):1083\u201397. https:\/\/doi.org\/10.1677\/ERC-08-0017.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4712_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000457954","volume":"106","author":"M Scharf","year":"2018","unstructured":"Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology. 2018;106(1):30\u20137. https:\/\/doi.org\/10.1159\/000457954.","journal-title":"Neuroendocrinology."},{"issue":"13","key":"4712_CR36","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330. https:\/\/doi.org\/10.1200\/JCO.2007.15.2553.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-020-04712-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T10:29:43Z","timestamp":1613298583000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-020-04712-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4712"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04712-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,15]]},"assertion":[{"value":"20 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"VP: Ipsen, ITG, Bayer (honoraria\/consultant); Ipsen (remuneration for travel, accommodation, expenses)RS: Ipsen, Novartis, Mylan (honoraria)CT: Ipsen, Novartis, Advanced Accelerator Applications (honoraria)CG: Norgine (remuneration for consultancy); Ipsen, Novartis, and Iason (remuneration for travel, accommodation, expenses)SB: NoneTS: Ipsen (honoraria, remuneration for consultancy, travel, accommodation, expenses)AL: Ipsen, Pfizer, Merck (remuneration for speaker\u2019s bureau); Ipsen, Pfizer, Novartis, AAA, Bayer, Delcath, SirTex (remuneration for travel, accommodation, expenses); EISAI, Nutricia (remuneration for consultancy)FC: Nalgene (remuneration for advisory board member\/board of directors); Advanced Accelerator Applications, Bayer (grant recipient); GEHC, Bayer, Advanced Accelerator Applications, Novartis, Ipsen (remuneration for speaker\u2019s bureau); GEHC, Bayer, Advanced Accelerator Applications, Novartis, Ipsen, Cyclopharma, Norgine (remuneration for travel, accommodation, expenses)KS: Ipsen, Shire (honoraria); Ipsen, Novartis, Shire, Eisa (remuneration for consultancy)EB: Ipsen, Novartis, Advanced Accelerator Applications, Pfizer (honoraria, remuneration for consultancy, grant recipient)XMTT and AH: Ipsen employeesCD: Ipsen (Honoraria, consultancy fees)LB: Ipsen, Advanced Accelerator Applications (honoraria, remuneration for consultancy, grant recipient)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen.com and will be assessed by a scientific review board. Data are available beginning 6\u00a0months and ending 5\u00a0years after publication; after this time, only raw data may be available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"France: E. Baudin, F. Courbon; Germany: V. Prasad, K. Scheidhauer; Italy: S. Baldari, C.M. Grana; L. Bodei (now USA); UK: A. Lamarca, T. Shah, R. Srirajaskanthan, C. Toumpanakis, J. Valle","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"PRELUDE study group"}}]}}